Being Metabolically Healthy, the Most Responsible Factor for Vascular Health

Eun-Jung Rhee
Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

The prevalence of obesity is rapidly increasing worldwide. One-thirds of world population is suffering from the deleterious effects of excessive fat and adipose tissue in their body. At the same time, the average life expectancy is becoming higher and higher every decade. Therefore, living healthy and longer is the dream for everyone. Simply being obese is not the primary cause for the consequence of obesity; rather, the depot where the fat is accumulated, is the primary key for the deleterious effects of obesity. Results from historical research suggest that visceral fat increases the risk for cardiovascular and metabolic diseases, such as diabetes, myocardial infarction and ischemic stroke, not subcutaneous fat. Therefore, body mass index (BMI), which reflects body weight relative to height might not reflect the appropriate size of metabolic burden of fat in our body. In contrast, waist circumference, which reflects abdominal obesity, would mirror the metabolic burden of fat better than BMI. Visceral fat is the marker of ectopic fat accumulation. In this review, I will introduce my researches mainly involved in uncovering the clues to the link between metabolic health and cardiovascular disease.

Keywords: Cardiovascular diseases; Metabolic syndrome; Obesity

INTRODUCTION

Obesity is renowned for its comorbid diseases, such as diabetes, atherosclerosis, metabolic syndrome (MetS) and sleep apnea [1-3]. The prevalence of obesity in adults older than 30 is reaching 30% worldwide, and this high rate of obesity is more pronounced in Asians, due to the rapid change of diet patterns and sedentary life style [4]. The propensity of Asians for high prevalence of visceral obesity contributes for the markedly increasing prevalence of diabetes and MetS [5]. The results of recent studies focus not only on the obesity itself, but on the depots where the fat is actually accumulating [6,7].

Abdominal obesity is known to be a major risk factor for diabetes and cardiovascular disease (CVD) [8]. The cluster of diseases, that is, ‘syndrome’ caused by abdominal obesity is called MetS [9]. It has long been considered as the main cause for the increased risk for CVD in subjects with abdominal obesity and many kinds of metabolic disease. The components of MetS insulin resistance, hypertension, hyperglycemia, systemic inflammation, atherogenic dyslipidemia and consequently, atherosclerosis (Fig. 1).

Kangbuk Samsung Health Study (KSHS) is one of the largest health screening cohort prospectively and retrospectively ongoing in Koreans, and it is known to screening more than 100,000 subjects every year. As a clinical and researcher working in Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, the author could have full access to the dataset of KSHS. In this review, I would like to discuss about the clinical implication and current knowledge about MetS and metabolically healthy obesity (MHO) and their impacts on vascular health, mainly focusing on the results analyzed from KSHS data.
PREVALENCE AND DEFINITION OF MetS

The prevalence of MetS is consistently being reported to be around 30% of the study population, which shows pretty constant rate in spite of different study population [10]. In a study performed in more than 40,698 Korean participants in KSHS, the prevalence of MetS differed according to the criteria used to diagnose MetS, and this study was the first study that suggested that different definition of abdominal obesity should be used in Asian population compared to that in Caucasians in the diagnosis of MetS [11].

A very initial study from our research group reported the relationship between systemic inflammation and insulin resistance [12]. In this study, we reported that MetS and insulin resistance are associated with systemic inflammation assessed by high C-reactive protein (CRP). In another study by Park et al. [13], those with high insulin resistance index assessed by homeostasis model assessment of insulin resistance (HOMA-IR) had significantly high risk for MetS compared with those with low HOMA-IR. In addition, we reported that in those with impaired fasting glucose, the insulin resistance index and high-sensitivity CRP (hs-CRP) increased gradually even in the normal fasting glucose range [14]. In reverse, in the study by Jung et al. [15], the risk for future MetS was the highest in those with the highest quartile of hs-CRP, suggesting the increased risk for MetS in those with high systemic inflammation.

MetS AND CARDIOVASCULAR RISK FACTORS

We reported some studies regarding the relationship between surrogate markers or indices related with glycemia and MetS. In 40,155 participants in KSHS, a glycosylated hemoglobin of 5.45% predicted the presence of MetS [16]. In the study by Park et al. [17], in 465 participants in whom adipocytokines were measured, those with higher baseline serum fatty-acid binding protein (FABP)-4 levels showed significant association with future development of MS after 4 years of follow-up. In another study by Sung et al. [18], in which 2,350 subjects were followed up for 4 years, those with high baseline fasting insulin levels were independently associated with future development of MetS. In the study by Kim et al. [19], higher serum alkaline phosphatase levels was a significant predictor for future MetS development, and Jung et al. [20] showed significant association of elevated white blood cell count with incident MetS.

MetS AND CARDIOVASCULAR RISK

Many studies already reported increased cardiovascular risk in subjects with MetS. Results from meta-analyses report 2- to 5-fold increased risk for cardiovascular mortality in subjects with MS [21]. The mechanisms for increased CVD risk in subjects with MetS are explained by the definition of MetS, in that, MetS itself is the cluster of cardiovascular risk factors [22]. Hyperinsulinemia, hyperglycemia, increased systemic inflammation and visceral obesity and dyslipidemia, all attribute to the development of atherosclerosis and consequent CVD.

In 155,971 participants in KSHS from 2002 to 2009 with mean age of 42 years without previous history of CVD (median follow-up of 3.7 years), mortality data were obtained based on nationwide death certificate data of Korea National Statistical Office [23]. We observed an increased risk for all-cause and CVD mortality in subjects with MetS. However, these increased risk were attenuated after exclusion of subjects with diabetes or hypertension, suggesting that inclusion of these extreme metabolic disease accounts for the increased CVD mortality attributable to MetS. The result of our study suggests reconciliation of existence of MetS or the need for re-definition of MetS.

Fig. 1. The components of metabolic health and metabolic syndrome.
THE DELETERIOUS EFFECTS OF ABDOMINAL OBESITY

Obesity could be defined by many parameters, such as increased waist circumference (WC), increased body mass index (BMI), increased weight, increased waist-hip ratio (WHR) and recently increased waist-height ratio (WHR) [24,25]. Recent researches support the deleterious effect of abdominal obesity versus affirmative effect of subcutaneous fat [26]. However, due to the convenience and the reproducibility, BMI is still frequently used in the screening of obesity in large study population.

Coronary artery calcification (CAC) is considered as a non-invasive, convenient, and accurate surrogate marker for the prediction of cardiovascular burden and CVD event from the results of many famous cohort studies [27]. In KSHS, around 10% of the participants perform coronary artery calcium score (CACS) test every year. Therefore, KSHS has a large cohort of CACS, followed up for many years.

Park et al. [28], analyzed the association among WC, BMI, and CAC. In 33,433 participants in KSHS in whom CACS were available, the risk for CAC increased as BMI increased with 1.3-fold increased risk of CAC in the obese group versus normal group. When the participants were divided into six groups according to BMI and WC, obese group defined by BMI with abdominal obesity showed the highest risk for CAC followed by those with BMI in the overweight range with abdominal obesity defined by WC, suggesting the WC as a marker of obesity is more predictive of CAC than BMI.

In 945 participants in KSHS, the association of body composition with CAC was analyzed [29]. Body composition analyses were performed with bioelectrical impedance analysis method and WHR was used as the marker of abdominal obesity. The subjects with high CACS showed significantly higher mean WHRs and lower mean values of Lean body mass compared with those without CAC. In logistic regression analysis with CAC as the dependent variable, those with the highest quartile of WHR showed a 3-fold increased risk for CAC compared with the lowest quartile of WHR, suggesting WHR was the significant predictor for CAC.

Recent studies suggest WHR as an easy and inexpensive adiposity index that reflects central obesity [30]. In 2,900 nondiabetic participants in KSHS, Son et al. [31] analyzed the association between baseline WHtR and development of diabetes after 4 years. The cutoff of WHtR for diabetes development was 0.51, and WHtR showed almost similar predictive effect for diabetes development as WC. In another study by Oh et al. [32], 1,048 male participants in KSHS were analyzed for the association between baseline WHtR and progression of CAC after 4 years. In this study, they showed that increased baseline WHtR was associated with increased risk of CAC progression after 4 years, suggesting WHtR might be a useful tool to identify individuals at high risk for subclinical atherosclerosis.

Nonalcoholic fatty liver disease (NAFLD) is considered as the marker of insulin resistance and ectopic fat accumulation [33]. Recent studies suggest NAFLD as the cardiovascular risk factors due to multiple mechanisms [34]. We wondered whether NAFLD or WC would predict CAC better than the other. In 21,335 male participants of KSHS in whom CACS data were available, we analyzed the association between NAFLD, abdominal obesity and CAC [35]. In logistic regression analysis with CAC as the dependent variable, those with NAFLD and abdominal obesity showed significantly increased risk of CAC compared with those without either abnormality. Interestingly, those with NAFLD but without abdominal obesity showed significantly increased risk for CAC with odds ratio of 1.286. In contrast, those with only abdominal obesity but without NAFLD did not show increased risk of CAC compared with those without either abnormalities, suggesting that NAFLD is more closely related with CAC than abdominal obesity.

Hypertriglyceridemic waist (HTGW) phenotype is a recently recommended concept that reflects those with high risk for CVD and also those with metabolically unhealthiness [36]. We divided 32,186 participants in KSHS into four groups with normal WC-normal triglyceride (TG) levels, normal WC-high TG levels, enlarged WC-normal TG levels, and enlarged WC-high TG levels [37], and analyzed their association with CAC. Those with enlarged WC and high TG levels showed the highest mean value of CACS followed by those with normal WC and high TG levels, suggesting this HTGW phenotype as a useful marker for detection of subjects with high cardiometabolic risk. In another study performed in 2,900 participants in KSHS, Han et al. [38] analyzed this HTGW phenotype with incident diabetes after 4 years. Those with enlarged WC and high TG showed 2.4-fold increased risk for diabetes development after 4 years, suggesting this HTGW phenotype could be a useful marker to detect those with high risk for diabetes.

Visceral adiposity index (VAI) is a mathematical tool that reflects a subject's visceral adiposity and insulin resistance [39]. Recent studies have noted an association between VAI and
cardiovascular event [40]. We analyzed the association between VAI and CACS in 33,468 participants in KSHS [41]. CACS was positively correlated with VAI and subjects with high CACS had significantly higher VAI compared to those with CACS of zero. The subjects with the highest tertile of VAI had significantly increased odds ratio for CACS >0 compared to subject in the lowest tertile. These results suggested that high VAI reflects increased risk for subclinical atherosclerosis.

The last concept that defines metabolic health we’ve been interested, was triglyceridemic glucose (TyG) index [42]. This index is calculated from fasting TG levels and fasting glucose levels and is used to detect those with high risk for cardiometabolic risk. 2,900 non-diabetic participants in KSHS in whom health checkup was performed for 5 consecutive years, were divided into four groups according to the quartile groups of baseline TyG index [43]. Those with the highest quartile of TyG index showed significantly increased risk for diabetes development compared to the first quartile of TyG index. In addition, those with high TyG index (≥8.8) and BMI ≥25 kg/m^2 showed significantly increased risk of diabetes development. From the results of this study, we found that TyG index could be a valuable marker for predicting diabetes.

**THE CONCEPT OF ‘METABOLICALLY HEALTHY OBESITY’**

In 2012, there was interesting news by Reuter with the headline “Obesity not always tied to higher heart risk” [44]. This news was raised from a study by Hamer and Stamatakis [45], reporting the association of MHO with cardiovascular mortality. In 22,203 men and women without known history of CVD at baseline, the subjects were divided into four groups; metabolically healthy non-obese, metabolically unhealthy non-obese, MHO, and metabolically unhealthy obese. The definition of metabolic health was made based on high blood pressure, low high density lipoprotein cholesterol, diagnosis of diabetes, enlarged WC and CRP ≥3 mg/L. Those with less than two components among these were defined as metabolically healthy. After adjustment for multiple risk factors, metabolically unhealthy obese subjects showed 1.6-fold increased risk for CVD mortality compared with metabolically healthy non-obese subjects. The subjects with MHO, that is, BMI in obese range but did not have sufficient metabolically unhealthy components, showed similar risk for CVD mortality compared to those with metabolically healthy non-obese subjects. After the release of this study, many studies were published regarding this concept [46,47]. MHO subjects seem to show very distinct features of decreased liver fat, increased mitochondrial function, decreased visceral adiposity and increased metabolic flexibility (Fig. 2).

We analyzed the association of MHO and CAC in KSHS cohort [48]. In 24,063 participants in KSHS in whom CACS data were available, metabolic health was defined by similar criteria as previously published studies. The subjects were divided into four groups according to metabolic health and obesity defined by BMI ≥25 kg/m^2. Metabolically unhealthy obese subjects had significantly increased (upto 1.9-fold) risk for CAC compared to those with metabolically healthy non-obese subjects. Similar to the previous study, MHO subjects did not show significantly increased risk for CAC, suggesting the existence of MHO. In another study performed in 6,748 non-diabetic subjects in KSHS, MHO subjects showed not increased risk for diabetes development after 4 years compared to metabolic healthy non-obese subjects, supporting the existence of MHO.

The last proof of importance of metabolic health was the study performed using adipocytokines [49]. In 456 non-diabetic participants in KSHS in whom adipocytokines were measured, the subjects were divided into four groups according to obesity status and metabolic health. There were no significant differences in interleukin 6 or monocyte chemoattractant protein-1 levels among the groups, but levels of tumor ne-
Importance of metabolic health on vascular health

crosis factor α and FABP-4 were significantly higher in the metabolically unhealthy non-obese group compared to the metabolically healthy non-obese group, suggesting the association of adipocytokines with metabolic health.

CONCLUSIONS

In this review, I introduced numerous studies performed with the dataset of KSHS, most of which are my own work. Our data has the advantages of multiple metabolic parameters and the abundance in cardiometabolic risk factors. The strongest point is the large number of the participants in many years of repetitive health checkup. Although they are retrospective data, we could arrange the dataset as the cross-sectional, retrospective and consecutive dataset.

From the analyses of our data, we published many papers on the prevalence and definition of MetS initially, and its association with CVD. In addition, we could uncover the relationship between cardiometabolic risk factors and MetS. Recently, we are focusing on the importance of abdominal obesity and metabolic health in the prevention of CVD. We could conclude that not just being obese, but having abdominal obesity is more deleterious for metabolic health and subsequent CVD risk. Therefore, we have to inform our patients that to prevent development of diabetes and atherosclerosis, healthy life style and weight control is important more than any other strategies.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. World Health Organization: Overweight and obesity. Available from: http://www.who.int/gho/ncd/risk_factors/overweight/en/ (cited 2017 Dec 31).
2. Jarolimova J, Tagoni J, Stern TA. Obesity: its epidemiology, comorbidities, and management. Prim Care Companion CNS Disord 2013;15:1201475.
3. Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev 2015; 95:727-48.
4. Kim MK, Lee WY, Kang JH, Kang JH, Kim BT, Kim SM, Kim EM, Suh SH, Shin HJ, Lee KR, Lee KY, Lee SY, Lee SY, Lee SK, Lee CB, Chung S, Jeong IK, Hur KY, Kim SS, Woo JT; Committee of Clinical Practice Guidelines; Korean Society for the Study of Obesity. 2014 Clinical practice guidelines for overweight and obesity in Korea. Endocrinol Metab (Seoul) 2014; 29:405-9.
5. Yajnik CS, Yudkin JS. The Y-Y paradox. Lancet 2004;363:163.
6. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell 2014;156:20-44.
7. Lim S. Ectopic fat assessment focusing on cardiometabolic and renal risk. Endocrinol Metab (Seoul) 2014;29:1-4.
8. Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res 2016;118: 1723-35.
9. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JJ, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
10. Lim S, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J, Choi SH, Cho SI, Park KS, Lee HK, Jang HC, Koh KK. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care 2011;34:1323-8.
11. Lee WY, Park JS, Noh SY, Rhee EJ, Kim SW, Zimmet PZ. Prevalence of the metabolic syndrome among 40,698 Korean metropolitan subjects. Diabetes Res Clin Pract 2004;65:143-9.
12. Lee WY, Park JS, Noh SY, Rhee EJ, Sung KC, Kim BS, Kang JH, Kim SW, Lee MH, Park JR. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int J Cardiol 2004;97:101-6.
13. Park SH, Lee WY, Rhee EJ, Jeon WK, Kim BI, Ryu SH, Kim SW. Relative risks of the metabolic syndrome according to the degree of insulin resistance in apparently healthy Korean adults. Clin Sci (Lond) 2005;108:553-9.
14. Rhee EJ, Kim YC, Lee WY, Jung CH, Sung KC, Ryu SH, Oh KW, Kim SW. Comparison of insulin resistance and serum
high-sensitivity C-reactive protein levels according to the fasting blood glucose subgroups divided by the newly recommended criteria for fasting hyperglycemia in 10,059 healthy Koreans. Metabolism 2006;55:183-7.

15. Jung CH, Lee WY, Kim SY, Shin HS, Kim HD, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW. The risk of metabolic syndrome according to the high-sensitivity C-reactive protein in apparently healthy Koreans. Int J Cardiol 2008;129:266-71.

16. Sung KC, Rhee EJ. Glycated haemoglobin as a predictor for metabolic syndrome in non-diabetic Korean adults. Diabet Med 2007;24:848-54.

17. Park SE, Rhee EJ, Lee WY, Kim WJ, Yoo SH, Bae JC, Choi ES, Park CY, Oh KW, Park SW, Kim SW. The role of serum adipocyte fatty acid-binding protein on the development of metabolic syndrome is independent of pro-inflammatory cytokines. Nutr Metab Cardiovasc Dis 2012;22:525-32.

18. Sung KC, Seo MH, Rhee EJ, Wilson AM. Elevated fasting insulin predicts the future incidence of metabolic syndrome: a 5-year follow-up study. Cardiovasc Diabetol 2011;10:108.

19. Kim MK, Baek KH, Kang MI, Park SE, Rhee EJ, Park CY, Lee WY, Oh KW. Serum alkaline phosphatase, body composition, and risk of metabolic syndrome in middle-aged Korean. Endocr J 2013;60:321-8.

20. Jung CH, Lee WY, Kim BY, Park SE, Rhee EJ, Park CY, Oh KW, Mok JO, Kim CH, Park SW, Kim SW, Kang SK. The risk of metabolic syndrome according to the white blood cell count in apparently healthy Korean adults. Yonsei Med J 2013;54:615-20.

21. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffirin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-32.

22. Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am 2014;43:1-23.

23. Sung KC, Rhee EJ, Ryu S, Kim BJ, Kim BS, Lee WY, Oh KW, Kim YB, Chung PW, Kim H, Byrne CD, Lee KB, Park SW. Increased cardiovascular mortality in subjects with metabolic syndrome is largely attributable to diabetes and hypertension in 159,971 Korean adults. J Clin Endocrinol Metab 2015;100:2606-12.

24. Hu D, Xie J, Fu P, Zhou J, Yu D, Whelton PK, He J, Gu D. Central rather than overall obesity is related to diabetes in the Chinese population: the InterASIA study. Obesity (Silver Spring) 2007;15:2809-16.

25. Lam BC, Koh GC, Chen C, Wong MT, Fallows SJ. Comparison of body mass index (BMI), Body adiposity index (BAI), waist circumference (WC), waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR) as predictors of cardiovascular disease risk factors in an adult population in Singapore. PLoS One 2015;10:e0122985.

26. Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. Int J Obes (Lond) 2008;32:619-28.

27. Blankstein R, Gupta A, Rana JS, Nasir K. The implication of coronary artery calcium testing for cardiovascular disease prevention and diabetes. Endocrinol Metab (Seoul) 2017;32:47-57.

28. Park J, Lee ES, Lee DY, Kim J, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. Waist circumference as a marker of obesity is more predictive of coronary artery calcification than body mass index in apparently healthy Korean adults: The Kangbuk Samsung Health Study. Endocrinol Metab (Seoul) 2016;31:559-66.

29. Yu JH, Yim SH, Yu SH, Lee JY, Kim JD, Seo MH, Jeon WS, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. The relationship of body composition and coronary artery calcification in apparently healthy Korean adults. Endocrinol Metab (Seoul) 2013;28:33-40.

30. Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0·5 could be a suitable global boundary value. Nutr Res Rev 2010;23:247-69.

31. Son YJ, Kim J, Park HJ, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. Association of waist-height ratio with diabetes risk: a 4-year longitudinal retrospective study. Endocrinol Metab (Seoul) 2016;31:127-33.

32. Byrne CD, Targher G. Ectopic fat, insulin resistance, and non-alcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 2014;34:1155-61.

33. Byrne CD, Tarhger G. Ectopic fat, insulin resistance, and non-alcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 2014;34:1155-61.

34. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012;33:1190-200.

35. Lee MK, Park HJ, Jeon WS, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. Higher association of coronary artery calcification with non-alcoholic fatty liver disease than with ab-
Importance of metabolic health on vascular health

36. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, Bergeron J, Gaudet D, Tremblay G, Prud’homme D, Nadeau A, Despres JP. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000;102:179-84.

37. Moon BS, Park HJ, Lee MK, Jeon WS, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. Increased association of coronary artery calcification in apparently healthy Korean adults with hypertriglyceridemic waist phenotype: the Kangbuk Samsung Health Study. Int J Cardiol 2015;194:78-82.

38. Han KJ, Lee SY, Kim NH, Chae HB, Lee TH, Jang CM, Yoo KM, Park HJ, Lee MK, Jeon WS, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. Increased risk of diabetes development in subjects with the hypertriglyceridemic waist phenotype: a 4-year longitudinal study. Endocrinol Metab (Seoul) 2014;29:514-21.

39. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A; AlkaMeSy Study Group. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010;33:920-2.

40. Han L, Fu KL, Zhao J, Wang ZH, Tang MX, Wang J, Wang H, Zhang Y, Zhang W, Zhong M. Visceral adiposity index score indicated the severity of coronary heart disease in Chinese adults. Diabetol Metab Syndr 2014;6:143.

41. Park HJ, Kim J, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. Increased risk of subclinical atherosclerosis associated with high visceral adiposity index in apparently healthy Korean adults: The Kangbuk Samsung Health Study. Ann Med 2016;48:410-6.

42. Lee SH, Han K, Yang HK, Kim HS, Cho JH, Kwon HS, Park YM, Cha BY, Yoon KH. A novel criterion for identifying metabolically obese but normal weight individuals using the product of triglycerides and glucose. Nutr Diabetes 2015;5:e149.

43. Lee DY, Lee ES, Kim JH, Park SE, Park CY, Oh KW, Park SW, Rhee EJ, Lee WY. Predictive value of triglyceride glucose index for the risk of incident diabetes: A 4-year retrospective longitudinal study. PLoS One 2016;11:e0163465.

44. Narayanan A: Obesity not always tied to higher heart risk: study. Available from: https://www.reuters.com/article/us-obesity-heartrisk/obesity-not-always-tied-to-higher-heart-risk-study-idUSBRE84N0VU20120524 (updated 2012 May 24).

45. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab 2012;97:2482-8.

46. Stefan N, Schick F, Haring HU. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab 2017;26:292-300.

47. Seo MH, Rhee EJ. Metabolic and cardiovascular implications of a metabolically healthy obesity phenotype. Endocrinol Metab (Seoul) 2014;29:427-34.

48. Rhee EJ, Seo MH, Kim JD, Jeon WS, Park SE, Park CY, Oh KW, Park SW, Lee WY. Metabolic health is more closely associated with coronary artery calcification than obesity. PLoS One 2013;8:e74564.

49. Lee TH, Jeon WS, Han KJ, Lee SY, Kim NH, Chae HB, Jang CM, Yoo KM, Park HJ, Lee MK, Park SE, Oh HG, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. Comparison of serum adipokine levels according to metabolic health and obesity status. Endocrinol Metab (Seoul) 2015;30:185-94.